Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

Norihiro Nishimoto, Jun Hashimoto, Nobuyuki Miyasaka, Kazuhiko Yamamoto, Shinichi Kawai, Tsutomu Takeuchi, Norikazu Murata, Desiree Der Van Heijde, Tadamitsu Kishimoto

Research output: Contribution to journalArticle

554 Citations (Scopus)

Abstract

Objective: To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA. Methods: In a multi-centre, x ray reader-blinded, randomised, controlled trial, 306 patients with active RA of <5 years' duration were allocated to receive either tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks or conventional disease-modifying antirheumatic drugs (DMARDs) for 52 weeks. Radiographs of hands and forefeet were scored by the van der Heijde modified Sharp method. Results: Patients had a mean disease duration of 2.3 years and a disease activity score in 28 joints of 6.5 at baseline. Mean total modified Sharp score (TSS) was 29.4, which was very high despite the relatively short disease duration. At week 52, the tocilizumab group showed statistically significantly less radiographic change in TSS (mean 2.3; 95% CI 1.5 to 3.2) than the DMARD group (mean 6.1; 95% CI 4.2 to 8.0; p<0.01). Tocilizumab monotherapy also improved signs and symptoms. The overall incidences of AEs were 89% and 82% (serious AEs: 18% and 13%; serious infections: 7.6% and 4.1%) in the tocilizumab and DMARD groups, respectively. Conclusion: Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA.

Original languageEnglish
Pages (from-to)1162-1167
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume66
Issue number9
DOIs
Publication statusPublished - 2007 Sep
Externally publishedYes

Fingerprint

Interleukin-6
Rheumatoid Arthritis
Randomized Controlled Trials
X-Rays
X rays
Antirheumatic Agents
Joints
Interleukin-6 Receptors
Signs and Symptoms
tocilizumab
Hand
Antibodies
Incidence
Infection

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. / Nishimoto, Norihiro; Hashimoto, Jun; Miyasaka, Nobuyuki; Yamamoto, Kazuhiko; Kawai, Shinichi; Takeuchi, Tsutomu; Murata, Norikazu; Van Heijde, Desiree Der; Kishimoto, Tadamitsu.

In: Annals of the Rheumatic Diseases, Vol. 66, No. 9, 09.2007, p. 1162-1167.

Research output: Contribution to journalArticle

Nishimoto, Norihiro ; Hashimoto, Jun ; Miyasaka, Nobuyuki ; Yamamoto, Kazuhiko ; Kawai, Shinichi ; Takeuchi, Tsutomu ; Murata, Norikazu ; Van Heijde, Desiree Der ; Kishimoto, Tadamitsu. / Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. In: Annals of the Rheumatic Diseases. 2007 ; Vol. 66, No. 9. pp. 1162-1167.
@article{adbd593d7bf74ed4aeed35c3cf337eb5,
title = "Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab",
abstract = "Objective: To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA. Methods: In a multi-centre, x ray reader-blinded, randomised, controlled trial, 306 patients with active RA of <5 years' duration were allocated to receive either tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks or conventional disease-modifying antirheumatic drugs (DMARDs) for 52 weeks. Radiographs of hands and forefeet were scored by the van der Heijde modified Sharp method. Results: Patients had a mean disease duration of 2.3 years and a disease activity score in 28 joints of 6.5 at baseline. Mean total modified Sharp score (TSS) was 29.4, which was very high despite the relatively short disease duration. At week 52, the tocilizumab group showed statistically significantly less radiographic change in TSS (mean 2.3; 95{\%} CI 1.5 to 3.2) than the DMARD group (mean 6.1; 95{\%} CI 4.2 to 8.0; p<0.01). Tocilizumab monotherapy also improved signs and symptoms. The overall incidences of AEs were 89{\%} and 82{\%} (serious AEs: 18{\%} and 13{\%}; serious infections: 7.6{\%} and 4.1{\%}) in the tocilizumab and DMARD groups, respectively. Conclusion: Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA.",
author = "Norihiro Nishimoto and Jun Hashimoto and Nobuyuki Miyasaka and Kazuhiko Yamamoto and Shinichi Kawai and Tsutomu Takeuchi and Norikazu Murata and {Van Heijde}, {Desiree Der} and Tadamitsu Kishimoto",
year = "2007",
month = "9",
doi = "10.1136/ard.2006.068064",
language = "English",
volume = "66",
pages = "1162--1167",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI)

T2 - Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

AU - Nishimoto, Norihiro

AU - Hashimoto, Jun

AU - Miyasaka, Nobuyuki

AU - Yamamoto, Kazuhiko

AU - Kawai, Shinichi

AU - Takeuchi, Tsutomu

AU - Murata, Norikazu

AU - Van Heijde, Desiree Der

AU - Kishimoto, Tadamitsu

PY - 2007/9

Y1 - 2007/9

N2 - Objective: To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA. Methods: In a multi-centre, x ray reader-blinded, randomised, controlled trial, 306 patients with active RA of <5 years' duration were allocated to receive either tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks or conventional disease-modifying antirheumatic drugs (DMARDs) for 52 weeks. Radiographs of hands and forefeet were scored by the van der Heijde modified Sharp method. Results: Patients had a mean disease duration of 2.3 years and a disease activity score in 28 joints of 6.5 at baseline. Mean total modified Sharp score (TSS) was 29.4, which was very high despite the relatively short disease duration. At week 52, the tocilizumab group showed statistically significantly less radiographic change in TSS (mean 2.3; 95% CI 1.5 to 3.2) than the DMARD group (mean 6.1; 95% CI 4.2 to 8.0; p<0.01). Tocilizumab monotherapy also improved signs and symptoms. The overall incidences of AEs were 89% and 82% (serious AEs: 18% and 13%; serious infections: 7.6% and 4.1%) in the tocilizumab and DMARD groups, respectively. Conclusion: Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA.

AB - Objective: To evaluate the ability of tocilizumab (a humanised anti-IL-6 receptor antibody) monotherapy to inhibit progression of structural joint damage in patients with RA. Methods: In a multi-centre, x ray reader-blinded, randomised, controlled trial, 306 patients with active RA of <5 years' duration were allocated to receive either tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks or conventional disease-modifying antirheumatic drugs (DMARDs) for 52 weeks. Radiographs of hands and forefeet were scored by the van der Heijde modified Sharp method. Results: Patients had a mean disease duration of 2.3 years and a disease activity score in 28 joints of 6.5 at baseline. Mean total modified Sharp score (TSS) was 29.4, which was very high despite the relatively short disease duration. At week 52, the tocilizumab group showed statistically significantly less radiographic change in TSS (mean 2.3; 95% CI 1.5 to 3.2) than the DMARD group (mean 6.1; 95% CI 4.2 to 8.0; p<0.01). Tocilizumab monotherapy also improved signs and symptoms. The overall incidences of AEs were 89% and 82% (serious AEs: 18% and 13%; serious infections: 7.6% and 4.1%) in the tocilizumab and DMARD groups, respectively. Conclusion: Tocilizumab monotherapy was generally well tolerated and provided radiographic benefit in patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=34447300492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447300492&partnerID=8YFLogxK

U2 - 10.1136/ard.2006.068064

DO - 10.1136/ard.2006.068064

M3 - Article

C2 - 17485422

AN - SCOPUS:34447300492

VL - 66

SP - 1162

EP - 1167

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 9

ER -